Scroll

simeprevir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Hepatitis Virus C (HVC) protease inhibitors	4812	923604-59-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: olysio TMC-435 TMC435350 simeprevir simeprevir sodium	Oral HCV-PROTEASE INHIBITOR effective against hepatitis C virus (HCV) serine protease NS3/4A. It is used in the treatment of chronic hepatitis C (Antivirals) genotype 1 infection in adults with compensated liver disease, including CIRRHOSIS. Molecular weight: 749.94 Formula: C38H47N5O7S2 CLOGP: 5.45 LIPINSKI: 3 HAC: 12 HDO: 2 TPSA: 156.89 ALOGS: -5.39 ROTB: 7 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

olysio
TMC-435
TMC435350
simeprevir
simeprevir sodium

Oral HCV-PROTEASE INHIBITOR effective against hepatitis C virus (HCV) serine protease NS3/4A. It is used in the treatment of chronic hepatitis C (Antivirals) genotype 1 infection in adults with compensated liver disease, including CIRRHOSIS.

Molecular weight: 749.94
Formula: C38H47N5O7S2
CLOGP: 5.45
LIPINSKI: 3
HAC: 12
HDO: 2
TPSA: 156.89
ALOGS: -5.39
ROTB: 7

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.15	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 2 of 2 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
May 14, 2014	EMA
Nov. 22, 2013	FDA	JANSSEN PRODS

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	786.23	38.65	301	4414	115821	63368486
Anaemia	585.05	38.65	325	4390	293105	63191202
White blood cell count decreased	471.06	38.65	221	4494	138883	63345424
Blood bilirubin increased	390.96	38.65	134	4581	37006	63447301
Neutrophil count decreased	278.13	38.65	117	4598	56289	63428018
Haemoglobin decreased	223.50	38.65	137	4578	145348	63338959
Hyperbilirubinaemia	167.78	38.65	53	4662	11261	63473046
Haemolytic anaemia	152.49	38.65	48	4667	10077	63474230
Hepatitis C	113.82	38.65	33	4682	5241	63479066
Hepatocellular carcinoma	111.22	38.65	27	4688	2167	63482140

Showing 1 to 10 of 21 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	553.02	28.77	300	5268	119417	34831946
White blood cell count decreased	397.78	28.77	224	5344	95221	34856142
Blood bilirubin increased	357.83	28.77	156	5412	38140	34913223
Anaemia	313.65	28.77	273	5295	233062	34718301
Hepatitis C	293.26	28.77	94	5474	9736	34941627
Hepatocellular carcinoma	262.22	28.77	81	5487	7428	34943935
Off label use	179.08	28.77	271	5297	419253	34532110
Hyperbilirubinaemia	174.62	28.77	74	5494	16769	34934594
Haemoglobin decreased	150.47	28.77	136	5432	120636	34830727
Neutrophil count decreased	144.78	28.77	94	5474	51010	34900353

Showing 1 to 10 of 30 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	1387.40	30.73	600	8990	194064	79540734
White blood cell count decreased	909.39	30.73	444	9146	187844	79546954
Anaemia	872.92	30.73	581	9009	444434	79290364
Blood bilirubin increased	700.00	30.73	272	9318	65960	79668838
Neutrophil count decreased	417.07	30.73	210	9380	93749	79641049
Hepatitis C	400.13	30.73	117	9473	11808	79722990
Haemoglobin decreased	377.43	30.73	267	9323	221852	79512946
Hepatocellular carcinoma	372.19	30.73	104	9486	8917	79725881
Hyperbilirubinaemia	320.99	30.73	118	9472	24400	79710398
Haemolytic anaemia	208.42	30.73	79	9511	17741	79717057

Showing 1 to 10 of 40 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J05AP05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections
FDA EPC	N0000182639	Hepatitis C Virus NS3/4A Protease Inhibitor
FDA MoA	N0000182138	Cytochrome P450 1A2 Inhibitors
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA MoA	N0000182638	HCV NS3/4A Protease Inhibitors
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190107	Organic Anion Transporting Polypeptide 1B1 Inhibitors
FDA MoA	N0000190108	Organic Anion Transporting Polypeptide 1B3 Inhibitors
FDA MoA	N0000190113	Breast Cancer Resistance Protein Inhibitors
FDA MoA	N0000193845	Bile Salt Export Pump Inhibitors

Showing 1 to 10 of 16 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic hepatitis C	indication	128302006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.35	acidic
pKa2	6.66	Basic
pKa3	3.5	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 150MG BASE	OLYSIO	JANSSEN PRODS	N205123	Nov. 22, 2013	DISCN	CAPSULE	ORAL	8349869	July 28, 2026	METHOD OF TREATING HEPATITIS C
EQ 150MG BASE	OLYSIO	JANSSEN PRODS	N205123	Nov. 22, 2013	DISCN	CAPSULE	ORAL	8741926	July 28, 2026	METHOD OF TREATING HEPATITIS C
EQ 150MG BASE	OLYSIO	JANSSEN PRODS	N205123	Nov. 22, 2013	DISCN	CAPSULE	ORAL	8754106	July 28, 2026	METHOD OF TREATING HEPATITIS C
EQ 150MG BASE	OLYSIO	JANSSEN PRODS	N205123	Nov. 22, 2013	DISCN	CAPSULE	ORAL	9040562	July 28, 2026	METHOD OF TREATING HEPATITIS C
EQ 150MG BASE	OLYSIO	JANSSEN PRODS	N205123	Nov. 22, 2013	DISCN	CAPSULE	ORAL	9353103	July 28, 2026	METHOD OF TREATING HEPATITIS C
EQ 150MG BASE	OLYSIO	JANSSEN PRODS	N205123	Nov. 22, 2013	DISCN	CAPSULE	ORAL	9623022	July 28, 2026	METHOD OF TREATING HEPATITIS C
EQ 150MG BASE	OLYSIO	JANSSEN PRODS	N205123	Nov. 22, 2013	DISCN	CAPSULE	ORAL	9856265	July 28, 2026	METHOD OF TREATING HEPATITIS C
EQ 150MG BASE	OLYSIO	JANSSEN PRODS	N205123	Nov. 22, 2013	DISCN	CAPSULE	ORAL	8148399	Sept. 5, 2029	METHOD OF TREATING HEPATITIS C

Showing 1 to 8 of 8 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Cathepsin S	Enzyme	P25774	CATS_HUMAN		IC50	6.10	CHEMBL
Hepatitis C virus serine protease, NS3/NS4A	Enzyme		A3EZI9_9HEPC D2K2A8_9HEPC	INHIBITOR	Ki	9.30	CHEMBL	CHEMBL
Genome polyprotein	Polyprotein		POLG_HCVH	INHIBITOR	Ki	9.44	SCIENTIFIC LITERATURE	DRUG LABEL
Nonstructural protein NS3-4A	Unclassified		A0A0K1CY61_9HEPC		Ki	9.44	CHEMBL
Polyprotein	Polyprotein		Q6GYR8_9HEPC	INHIBITOR	Ki	9.44	IUPHAR
Genome polyprotein	Unclassified		A3EZJ3_9HEPC		Ki	9.30	CHEMBL

Showing 1 to 6 of 6 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
015309	NDDF
015310	NDDF
1241946-89-3	SECONDARY_CAS_RN
1482790	RXNORM
207569	MMSL
24873435	PUBCHEM_CID
29896	MMSL
30B	PDB_CHEM_ID
4032900	VANDF
708823009	SNOMEDCT_US

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

None